UK markets closed

Alto Neuroscience, Inc. (ANRO)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
13.86-0.30 (-2.12%)
As of 02:31PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 380.68M
Enterprise value 308.12M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-31.59%
S&P500 52-week change 326.16%
52-week high 324.00
52-week low 312.78
50-day moving average 314.60
200-day moving average 315.02

Share statistics

Avg vol (3-month) 3177.12k
Avg vol (10-day) 386.44k
Shares outstanding 526.88M
Implied shares outstanding 626.88M
Float 819.31M
% held by insiders 113.11%
% held by institutions 141.60%
Shares short (30 Apr 2024) 42.49M
Short ratio (30 Apr 2024) 424.07
Short % of float (30 Apr 2024) 411.76%
Short % of shares outstanding (30 Apr 2024) 49.26%
Shares short (prior month 28 Mar 2024) 42.4M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-34.38%
Return on equity (ttm)-67.95%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -37.44M
Net income avi to common (ttm)-36.3M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)82.55M
Total cash per share (mrq)3.07
Total debt (mrq)9.99M
Total debt/equity (mrq)14.03%
Current ratio (mrq)15.22
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-33.45M
Levered free cash flow (ttm)-23.45M